Could Hamilton Thorne Ltd Lose its Strength? The Stock Reaches 52-Week High

 Could Hamilton Thorne Ltd Lose its Strength? The Stock Reaches 52 Week High

The stock of Hamilton Thorne Ltd (CVE:HTL) hit a new 52-week high and has $0.61 target or 64.00% above today’s $0.37 share price. The 8 months bullish chart indicates low risk for the $29.19 million company. The 1-year high was reported on Nov, 16 by Barchart.com. If the $0.61 price target is reached, the company will be worth $18.68 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 98,500 shares traded hands or 128.60% up from the average. Hamilton Thorne Ltd (CVE:HTL) has risen 6.00% since October 17, 2016 and is uptrending. It has outperformed by 1.31% the S&P500.

More notable recent Hamilton Thorne Ltd (CVE:HTL) news were published by: Marketwired.com which released: “Hamilton Thorne Announces the Acquisition of Embryotech Laboratories” on September 16, 2016, also Marketwired.com with their article: “Hamilton Thorne to Present at The MicroCap Conference” published on October 30, 2015, Marketwired.com published: “Hamilton Thorne Releases Updated Version of Its World-Leading Computer …” on October 13, 2016. More interesting news about Hamilton Thorne Ltd (CVE:HTL) were released by: Prnewswire.com and their article: “Merck KGaA, Darmstadt, Germany, Welcomes ZEISS and Hamilton Thorne as New …” published on June 30, 2016 as well as Marketwired.com‘s news article titled: “Hamilton Thorne Launches New Dimensions II Strict Morphology Software for the …” with publication date: October 14, 2013.

Hamilton Thorne Ltd. is engaged in the development, manufacture and sale of precision laser devices and advanced image analysis systems for living cell applications in the fertility, stem cell and developmental biology research markets. The company has a market cap of $29.19 million. The Firm offers Clinical lasers, Research lasers and Clinical Sperm Analysis Products. It has a 31.09 P/E ratio. The Company’s Clinical lasers include LYKOS laser and ZILOS-tk laser for applications, such as laser-assisted hatching and embryo biopsy for pre-implantation genetic diagnosis .

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment